{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:33:39Z","timestamp":1792481619953,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In 2021, the tubarial salivary glands (TSGs) were newly identified on prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) as macroscopic glands in the nasopharyngeal wall. However, the relative contribution of the TSGs to the total salivary gland function, and consequently on the development of xerostomia after external beam radiotherapy (EBRT) or PSMA-targeted radionuclide therapy (RNT) is not known. Therefore, we aimed to determine the presence of the TSGs and to quantify uptake in the TSGs on PSMA PET.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Qualitative and quantitative analyses were performed on <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT scans of 100 patients with prostate cancer. The mean and maximum standardized uptake value (SUVmean and SUVmax) in the TSGs were measured and compared to the parotid, submandibular and sublingual salivary glands (PSGs, SMSGs and SLSGs, respectively). Furthermore, proportional function of the TSGs was compared to the PSGs, SMSGs and SLSGs based on the total organ PSMA (TO-PSMA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The TSGs were visible on 95% of the <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT scans. The normalized median SUVmean and SUVmax was significantly higher for the PSGs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and SMSGs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) compared to the TSGs, but not for the SLSGs (<jats:italic>p<\/jats:italic>\u2009=\u20090.242 and <jats:italic>p<\/jats:italic>\u2009=\u20090.300, respectively). The normalized median TO-PSMA was significantly higher for the PSGs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and SMSGs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and significant lower for the SLSGs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) compared the TSGs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The SUVmean, SUVmax and TO-PSMA of the TSGs were most comparable to the SLSGs. However, the measured PSMA uptake may be disproportional towards the saliva production. Therefore, future studies should focus on the relation between PSMA uptake and salivary function before and after PSMA therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12149-024-01965-x","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T23:03:22Z","timestamp":1722035002000},"page":"913-918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tubarial salivary glands show a low relative contribution to functional salivary gland tissue mass"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-631X","authenticated-orcid":false,"given":"Sui wai","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Segbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Luiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Brabander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"issue":"10","key":"1965_CR1","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3390\/pharmaceutics14102166","volume":"14","author":"SW Ling","year":"2022","unstructured":"Ling SW, de Blois E, Hooijman E, van der Veldt A, Brabander T. Advances in 177Lu-PSMA and 225Ac-PSMA radionuclide therapy for metastatic castration-resistant prostate cancer. Pharmaceutics. 2022;14(10):2166.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1965_CR2","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1965_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","volume":"52","author":"SD Sweat","year":"1998","unstructured":"Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637\u201340.","journal-title":"Urology"},{"issue":"6","key":"1965_CR4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3390\/cancers12061367","volume":"12","author":"W Jones","year":"2020","unstructured":"Jones W, Griffiths K, Barata PC, Paller CJ. PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Cancers (Basel). 2020;12(6):1367.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1965_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/pros.21065","volume":"70","author":"V Yao","year":"2010","unstructured":"Yao V, Berkman CE, Choi JK, O\u2019Keefe DS, Bacich DJ. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate. 2010;70(3):305\u201316.","journal-title":"Prostate"},{"issue":"4","key":"1965_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","volume":"50","author":"P Mhawech-Fauceglia","year":"2007","unstructured":"Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50(4):472\u201383.","journal-title":"Histopathology"},{"issue":"2","key":"1965_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12105-021-01376-8","volume":"16","author":"H Nishida","year":"2022","unstructured":"Nishida H, Kondo Y, Kusaba T, Kadowaki H, Daa T. Immunohistochemical reactivity of prostate-specific membrane antigen in salivary gland tumors. Head Neck Pathol. 2022;16(2):427\u201333.","journal-title":"Head Neck Pathol"},{"issue":"11","key":"1965_CR8","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256\u201361.","journal-title":"Cancer"},{"issue":"1","key":"1965_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","volume":"1","author":"GL Wright Jr","year":"1995","unstructured":"Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1(1):18\u201328.","journal-title":"Urol Oncol"},{"issue":"4","key":"1965_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517\u201323.","journal-title":"J Nucl Med"},{"issue":"2","key":"1965_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","volume":"52","author":"P Jackson","year":"2022","unstructured":"Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi KA. Radiation dosimetry in (177)Lu-PSMA-617 therapy. Semin Nucl Med. 2022;52(2):243\u201354.","journal-title":"Semin Nucl Med"},{"issue":"2","key":"1965_CR12","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.18632\/oncotarget.12240","volume":"8","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Reinhardt S, Ilhan H, Delker A, Boning G, Gildehaus FJ, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581\u201390.","journal-title":"Oncotarget"},{"key":"1965_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.radonc.2020.09.034","volume":"154","author":"MH Valstar","year":"2021","unstructured":"Valstar MH, de Bakker BS, Steenbakkers R, de Jong KH, Smit LA, Klein Nulent TJW, et al. The tubarial salivary glands: a potential new organ at risk for radiotherapy. Radiother Oncol. 2021;154:292\u20138.","journal-title":"Radiother Oncol"},{"key":"1965_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","volume":"98\u201399","author":"N Heynickx","year":"2021","unstructured":"Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A. The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: a review of the lessons learnt so far. Nucl Med Biol. 2021;98\u201399:30\u20139.","journal-title":"Nucl Med Biol"},{"issue":"8","key":"1965_CR15","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1097\/RLU.0000000000003583","volume":"46","author":"P Sakthivel","year":"2021","unstructured":"Sakthivel P, Thakar A, Arunraj ST, Prashanth A, Kumar R, Sharma SC, Kumar R. Physiological PSMA uptake in the tubarial salivary glands and its implications in the PARIS protocol-a first study of its kind! Clin Nucl Med. 2021;46(8):e398\u2013405.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1965_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/JU.0000000000001012","volume":"204","author":"HB Luiting","year":"2020","unstructured":"Luiting HB, van Leeuwen PJ, Remmers S, Donswijk M, Busstra MB, Bakker IL, et al. Optimal timing of prostate specific membrane antigen positron emission tomography\/computerized tomography for biochemical recurrence after radical prostatectomy. J Urol. 2020;204(3):503\u201310.","journal-title":"J Urol"},{"key":"1965_CR17","unstructured":"EANM. EARL PET\/CT Accreditation User Manual Version 4.2 (May2023) \u00a9EARL 2023. Available from: https:\/\/earl.eanm.org\/wp-content\/uploads\/2023\/05\/EARL_Manual_4.2.pdf."},{"issue":"12","key":"1965_CR18","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","volume":"58","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial experience with volumetric (68)Ga-PSMA I&T PET\/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017;58(12):1962\u20138.","journal-title":"J Nucl Med"},{"issue":"9","key":"1965_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/joor.12664","volume":"45","author":"AML Pedersen","year":"2018","unstructured":"Pedersen AML, Sorensen CE, Proctor GB, Carpenter GH, Ekstrom J. Salivary secretion in health and disease. J Oral Rehabil. 2018;45(9):730\u201346.","journal-title":"J Oral Rehabil"},{"issue":"11","key":"1965_CR20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3390\/pharmaceutics11110560","volume":"11","author":"EAM Ruigrok","year":"2019","unstructured":"Ruigrok EAM, van Weerden WM, Nonnekens J, de Jong M. The future of PSMA-targeted radionuclide therapy: an overview of recent preclinical research. Pharmaceutics. 2019;11(11):560.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1965_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","volume":"25","author":"F Wang","year":"2022","unstructured":"Wang F, Li Z, Feng X, Yang D, Lin M. Advances in PSMA-targeted therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(1):11\u201326.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"1965_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00259-018-4135-8","volume":"46","author":"H Rathke","year":"2019","unstructured":"Rathke H, Kratochwil C, Hohenberger R, Giesel FL, Bruchertseifer F, Flechsig P, et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing (225) Ac-PSMA-617 RLT. Eur J Nucl Med Mol Imaging. 2019;46(1):139\u201347.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1965_CR23","doi-asserted-by":"publisher","first-page":"531660","DOI":"10.3389\/fonc.2020.531660","volume":"10","author":"ML Belli","year":"2020","unstructured":"Belli ML, Sarnelli A, Mezzenga E, Cesarini F, Caroli P, Di Iorio V, et al. Targeted alpha therapy in mCRPC (metastatic castration-resistant prostate cancer) patients: predictive dosimetry and toxicity modeling of (225) Ac-PSMA (prostate-specific membrane antigen). Front Oncol. 2020;10:531660.","journal-title":"Front Oncol"},{"issue":"8","key":"1965_CR24","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1007\/s00259-020-05150-w","volume":"48","author":"TM Kalidindi","year":"2021","unstructured":"Kalidindi TM, Lee SG, Jou K, Chakraborty G, Skafida M, Tagawa ST, et al. A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2021;48(8):2642\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1965_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2967\/jnumed.119.229393","volume":"61","author":"SR Banerjee","year":"2020","unstructured":"Banerjee SR, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, et al. Preclinical evaluation of (203\/212)Pb-Labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2020;61(1):80\u20138.","journal-title":"J Nucl Med"},{"issue":"9","key":"1965_CR26","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.3390\/ijms22094815","volume":"22","author":"VY Stenberg","year":"2021","unstructured":"Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland OS, Juzeniene A. Evaluation of the PSMA-binding ligand (212)Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer. Int J Mol Sci. 2021;22(9):4815.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1965_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s41181-024-00237-3","volume":"9","author":"SS Huang","year":"2024","unstructured":"Huang SS, DiFilippo FP, Lindner DJ, Heston WD. A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [(68)Ga]Ga-PSMA-11. EJNMMI Radiopharm Chem. 2024;9(1):7.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"2","key":"1965_CR28","first-page":"e53769","volume":"16","author":"K Agarwal","year":"2024","unstructured":"Agarwal K, Kumar PSN, Kumar P, Garg A, Nigam J, Silambarasan NS. Feasibility of achieving dose constraints for dysphagia aspiration-related structures and its clinical significance in intensity-modulated radiotherapy planning of head and neck cancer. Cureus. 2024;16(2):e53769.","journal-title":"Cureus"},{"issue":"8","key":"1965_CR29","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamaoncol.2023.1352","volume":"9","author":"J Castelli","year":"2023","unstructured":"Castelli J, Thariat J, Benezery K, Hasbini A, Gery B, Berger A, et al. Weekly adaptive radiotherapy vs standard intensity-modulated radiotherapy for improving salivary function in patients with head and neck cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9(8):1056\u201364.","journal-title":"JAMA Oncol"},{"issue":"20","key":"1965_CR30","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.3390\/jcm10204653","volume":"10","author":"T Weissmann","year":"2021","unstructured":"Weissmann T, Speer S, Putz F, Lettmaier S, Schubert P, Shariff M, et al. Reduction of elective radiotherapy treatment volume in definitive treatment of locally advanced head and neck cancer-comparison of a prospective trial with a revised simulated contouring approach. J Clin Med. 2021;10(20):4653.","journal-title":"J Clin Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-024-01965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-024-01965-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-024-01965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T04:21:06Z","timestamp":1729311666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-024-01965-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1965"],"URL":"https:\/\/doi.org\/10.1007\/s12149-024-01965-x","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethical committee at the Erasmus Medical Center, Rotterdam, the Netherlands (MEC-2016\u2013519) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patient for publication of this study and accompanying images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the patients gave written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}